Tg Therapeutics Stock Fundamentals

Stocks . USA . 
Stock . TG Therapeutics
TGTX Stock  USD 42.99  1.10  2.63%   
TG Therapeutics fundamentals help investors to digest information that contributes to TG Therapeutics' financial success or failures. It also enables traders to predict the movement of TGTX Stock. The fundamental analysis module provides a way to measure TG Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to TG Therapeutics stock.
Short Term DebtCurrent Deferred Revenue
At this time, TG Therapeutics' Income Tax Expense is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 162 M in 2025, whereas Depreciation And Amortization is likely to drop slightly above 195.5 K in 2025.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

TG Therapeutics Company Return On Equity Analysis

TG Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current TG Therapeutics Return On Equity

    
  0.12  
Most of TG Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, TG Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

TGTX Total Stockholder Equity

Total Stockholder Equity

233.48 Million

At this time, TG Therapeutics' Total Stockholder Equity is fairly stable compared to the past year.
Based on the latest financial disclosure, TG Therapeutics has a Return On Equity of 0.1222. This is 100.51% lower than that of the Biotechnology sector and 100.34% lower than that of the Health Care industry. The return on equity for all United States stocks is 139.42% lower than that of the firm.

TG Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining TG Therapeutics's current stock value. Our valuation model uses many indicators to compare TG Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across TG Therapeutics competition to find correlations between indicators driving TG Therapeutics's intrinsic value. More Info.
JavaScript chart by amCharts 3.21.15EXELVKTXXFORTERNAKROICPTTGTX -0.5-0.4-0.3-0.2-0.100.1 -0.8-0.6-0.4-0.200.2
TG Therapeutics is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers reporting about  0.47  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for TG Therapeutics is roughly  2.11 . At this time, TG Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the TG Therapeutics' earnings, one of the primary drivers of an investment's value.

TGTX Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses TG Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of TG Therapeutics could also be used in its relative valuation, which is a method of valuing TG Therapeutics by comparing valuation metrics of similar companies.
0.12220.2313-0.179-0.2635-0.2828100%
TG Therapeutics is currently under evaluation in return on equity category among its peers.

TG Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of TG Therapeutics from analyzing TG Therapeutics' financial statements. These drivers represent accounts that assess TG Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of TG Therapeutics' important valuation drivers and their relationship over time.
202020212022202320242025 (projected)
Market Cap980.9M6.0B1.6B2.4B4.4B4.6B
Enterprise Value909.1M5.5B1.6B2.4B4.4B4.7B

TG Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, TG Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to TG Therapeutics' managers, analysts, and investors.
53.9%
Environmental
56.3%
Governance
Social

TGTX Fundamentals

Return On Equity0.12
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%0%100%200%300%
Return On Asset0.0578
Profit Margin0.07 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%50,000%100,000%150,000%200,000%
Operating Margin0.28 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%50,000%100,000%150,000%200,000%
Current Valuation6.52 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%5,000%10,000%15,000%20,000%25,000%
Shares Outstanding157.07 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3120,000,000%40,000,000%60,000,000%80,000,000%
Shares Owned By Insiders9.41 %
Shares Owned By Institutions62.81 %
Number Of Shares Shorted25.74 M
Price To Earning(4.14) X
Price To Book30.00 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%20,000%40,000%60,000%80,000%100,000%
Price To Sales20.00 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312,000,000%4,000,000%6,000,000%8,000,000%
Revenue329 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%50,000%100,000%150,000%200,000%250,000%300,000%350,000%
Gross Profit290.52 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%50,000%100,000%150,000%200,000%250,000%300,000%
EBITDA49.9 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%2,000%4,000%6,000%8,000%
Net Income23.38 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%2,000%4,000%6,000%8,000%10,000%
Cash And Equivalents195.71 M
Cash Per Share1.45 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Total Debt253.72 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%5,000%10,000%15,000%20,000%25,000%30,000%
Debt To Equity0.62 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-140%-120%-100%-80%-60%-40%-20%
Current Ratio4.68 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%
Book Value Per Share1.54 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Cash Flow From Operations(40.52 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%1,000%2,000%3,000%4,000%5,000%6,000%7,000%
Short Ratio14.83 X
Earnings Per Share0.15 X
Target Price42.83
Number Of Employees338
Beta2.3
Market Capitalization6.58 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150,000%100,000%150,000%200,000%250,000%300,000%
Total Asset577.69 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-315,000%10,000%15,000%20,000%25,000%
Retained Earnings(1.53 B)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%5,000%10,000%15,000%
Working Capital475.68 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Current Asset71.33 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-315,000%10,000%15,000%20,000%25,000%
Current Liabilities16.88 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-315,000%10,000%15,000%20,000%25,000%30,000%
Net Asset577.69 M

About TG Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze TG Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TG Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TG Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue11.4 M12 M
Total Revenue329 M345.5 M
Cost Of Revenue38.5 M23.1 M
Stock Based Compensation To Revenue 0.13  0.12 
Sales General And Administrative To Revenue 0.47  0.45 
Research And Ddevelopement To Revenue 0.29  0.27 
Revenue Per Share 2.26  2.15 
Ebit Per Revenue 0.13  0.13 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
SSentinelOne
GMGeneral Motors

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.


 
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY